
EMA Recommends Brodalumab for Approval
The agency’s Committee for Medicinal Products for Human Use recommended AstraZeneca’s brodalumab for the treatment of moderate-to-severe plaque psoriasis.
On May 19, 2017, AstraZeneca announced that its partner LEO Pharma has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending the approval of brodalumab for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Brodalumab is a fully human monoclonal antibody that selectively targets the IL-17 receptor. By binding to the receptor, brodalumab blocks the biological activity of several pro-inflammatory IL-17 cytokines.
In July 2016, AstraZeneca
Siliq comes with a boxed warning for a potential link to suicidal ideation. In 2015, Amgen
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.